RxDoctor Payments Data

Enrique Leal, MD

Family Medicine · Sweeny, TXNPI 1972664076

Payments from drug & device makers

$1,189in general payments, 2019–2025

Across 35 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$667
  • Astellas Pharma US Inc$128
  • AbbVie$70
  • Lilly USA, LLC$69
  • Novo Nordisk$66
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$38
  • plus $151 from 8 others

What the payments were for

  • Food & beverage$1,08992%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,189 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$67,055
Medicare patients
229
Services billed
1,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$133,555
EliquisApixaban126$85,452
XifaxanRifaximin25$33,211
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$29,457
JardianceEmpagliflozin23$26,633
FarxigaDapagliflozin Propanediol36$23,805
XareltoRivaroxaban26$23,050
JanuviaSitagliptin Phosphate21$20,492
EntrestoSacubitril/Valsartan13$9,961
TradjentaLinagliptin12$8,356
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$7,398
Tresiba Flextouch U-100Insulin Degludec17$7,285
Atorvastatin Calcium425$5,062
Albuterol Sulfate HfaAlbuterol Sulfate138$4,444
Memantine Hcl45$4,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$66$133,555111 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$38$33,21125 claims
AstraZenecaFarxiga$31$23,80536 claims
Lilly USA, LLCHumulin 70-30$69$1,61212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sweeny

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →